Effect of Esketamine on postoperative recovery quality and inflammatory response in patients with modified radical mastectomy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000034930

Enrollment

Unknown

Registered

2020-07-24

Start date

2020-11-01

Completion date

Unknown

Last updated

2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Group 1:Esketamine was induced by 0.1mg/kg and maintained by 0.1mg/kg/h

Group 2:Esketamine was induced by 0.2mg/kg and maintained by 0.2mg/kg/h

Group 3:During induction period and maintenance period, the same volume of normal saline was injected into the control group, 0.1ml/kg IV, followed by 0.1ml/kg/h

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. ASA : I-II; 2. Aged 18-60 years; 3. Women; 4. Unilateral modified radical mastectomy is proposed.

Exclusion criteria

Exclusion criteria: 1. Allergic to drugs in the study plan; 2. Associated with increased blood pressure, intraocular pressure, diabetes, cardiovascular and cerebrovascular diseases, mental diseases, other malignant tumors, or abnormal liver and kidney functions; 3.Take drugs that affect your immune function; 4. Inflammatory breast cancer; 5. Previous breast cancer surgery; 6. Preoperative chemoradiotherapy was performed; 7. BMI > 30 kg/m2; 8. Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
QoR-40;NLR;	—

Secondary

Measure	Time frame
Mechanical pain threshold;NRS;	—

Countries

China

Contacts

Public ContactHongying Tan

Cancer Center, Sun Yat-Sen University

tanhongy@sysucc.org.cn+86 13556063870

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026